NCT03493451 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 77
- units
- Participants
- groups
- description
- Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- BG000
- title
- Cohort 1: ENKTL
- description
- Participants with other R/R mature T-cell neoplasms \[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- BG001
- title
- Cohort 2: PTCL-NOS, AITL, and ALCL
- description
- Participants with R/R cutaneous T-cell lymphoma \[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- BG002
- title
- Cohort 3: MF and SS
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 16.24
- value
- 51.5
- group Id
- BG001
- spread
- 15.03
- value
- 55.8
- group Id
- BG002
- spread
- 12.45
- value
- 59.4
- group Id
- BG003
- spread
- 15.09
- value
- 55.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 26
- title
- Female
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 51
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 44
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 28
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 41
- title
- China
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Taiwan
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 28
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- France
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 77
- units
- Participants
- groups
- description
- Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- BG000
- title
- Cohort 1: ENKTL
- description
- Participants with other R/R mature T-cell neoplasms \[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- BG001
- title
- Cohort 2: PTCL-NOS, AITL, and ALCL
- description
- Participants with R/R cutaneous T-cell lymphoma \[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- BG002
- title
- Cohort 3: MF and SS
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 16.24
- value
- 51.5
- group Id
- BG001
- spread
- 15.03
- value
- 55.8
- group Id
- BG002
- spread
- 12.45
- value
- 59.4
- group Id
- BG003
- spread
- 15.09
- value
- 55.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 26
- title
- Female
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 51
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 44
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 28
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 41
- title
- China
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Taiwan
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 28
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- France
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle